BioLineRx (BLRX) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$0.66

+0.02 (+3.14%)

(As of 04/19/2024 ET)

Source

Source	Headline
	HC Wainwright Reiterates "Buy" Rating for BioLineRx (NASDAQ:BLRX) americanbankingnews.com - April 19 at 1:58 AM
	Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency markets.businessinsider.com - April 18 at 10:09 AM
	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting finance.yahoo.com - April 17 at 8:53 AM
	BioLineRx (NASDAQ:BLRX) Raised to Sell at StockNews.com americanbankingnews.com - April 14 at 1:44 AM
	BioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.com marketbeat.com - April 12 at 11:18 PM
	BioLineRx secures $20 million in BlackRock financing investing.com - April 11 at 10:42 PM
	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement finance.yahoo.com - April 10 at 9:47 AM
	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement prnewswire.com - April 10 at 7:00 AM
	BioLineRx Announces $6 Million Registered Direct Offering prnewswire.com - April 1 at 9:00 AM
	FY2024 Earnings Forecast for BioLineRx Ltd. (NASDAQ:BLRX) Issued By HC Wainwright marketbeat.com - March 29 at 8:38 AM
	Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 76.6% marketbeat.com - March 28 at 4:32 PM
	BioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates finanznachrichten.de - March 28 at 2:26 PM
	Research Analysts Issue Forecasts for BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX) marketbeat.com - March 28 at 8:22 AM
	BioLineRx (NASDAQ:BLRX) Upgraded to Sell at StockNews.com marketbeat.com - March 27 at 11:16 PM
	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 27 at 12:31 PM
	BLRX: First Aphexda Sales Recognized finance.yahoo.com - March 27 at 12:31 PM
	BioLineRx (NASDAQ:BLRX) Announces Earnings Results marketbeat.com - March 27 at 9:30 AM
	Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism markets.businessinsider.com - March 27 at 12:47 AM
	BioLineRx's (BLRX) "Buy" Rating Reiterated at HC Wainwright marketbeat.com - March 26 at 12:44 PM
	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates prnewswire.com - March 26 at 7:00 AM
	BioLineRx (BLRX) to Release Quarterly Earnings on Tuesday marketbeat.com - March 21 at 11:26 AM
	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 prnewswire.com - March 20 at 7:00 AM
	BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Decrease in Short Interest marketbeat.com - March 19 at 8:39 AM
	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production finance.yahoo.com - March 4 at 7:38 AM
	BioLineRx begins phase 2 trial for pancreatic cancer treatment investing.com - March 1 at 10:23 AM
	BLRX Mar 2024 1.000 call finance.yahoo.com - March 1 at 10:23 AM
	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) prnewswire.com - February 28 at 7:00 AM
	BLRX: Poster Presentations finance.yahoo.com - February 26 at 2:18 PM
	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond investorplace.com - February 25 at 2:12 PM
	BLRX May 2024 1.000 put ca.finance.yahoo.com - February 23 at 2:16 PM
	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® finance.yahoo.com - February 16 at 7:15 AM
	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® prnewswire.com - February 16 at 7:00 AM
	BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Drop in Short Interest marketbeat.com - December 29 at 12:17 PM
	BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease finance.yahoo.com - December 21 at 10:12 AM
	BioLineRx: Still A Buy, With Some Questions seekingalpha.com - December 4 at 11:58 PM
	BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges seekingalpha.com - December 3 at 10:01 AM
	BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript insidermonkey.com - November 21 at 5:06 PM
	Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth markets.businessinsider.com - November 21 at 10:12 AM
	BLRX: A Series of Fortunate Events finance.yahoo.com - November 21 at 10:12 AM
	BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates finance.yahoo.com - November 20 at 8:10 AM
	biolinerx Q3 2023 Earnings Preview msn.com - November 17 at 2:28 PM
	BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 finance.yahoo.com - November 13 at 7:32 AM
	Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7B msn.com - November 5 at 8:08 AM
	BioLineRx Shares Rise 12% After Licensing Agreement for Motixafortide marketwatch.com - November 2 at 7:25 PM
	MSQ Ventures: BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures finanznachrichten.de - October 31 at 9:28 AM
	BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures finance.yahoo.com - October 31 at 9:28 AM
	BioLineRx Concludes License Deal With Guangzhou Gloria To Develop Motixafortide In Asia markets.businessinsider.com - October 12 at 9:18 AM
	BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment finance.yahoo.com - October 12 at 9:18 AM
	BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results thestreet.com - October 9 at 7:08 PM
	BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer msn.com - September 28 at 2:21 PM

Get BioLineRx News Delivered to You Automatically

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

BLRX Media Mentions By Week

BLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLRX
News Sentiment
▼
0.12

0.52
▲
Average
Medical
News Sentiment

BLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLRX Articles
This Week
▼
6

1
▲
BLRX Articles
Average Week

Get BioLineRx News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:BLRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioLineRx (BLRX) News Today

BLRX Media Mentions By Week

BLRX Media Sentiment

BLRX News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info